The Finnish trial of prostate cancer screening: where are we now?
Finne
P
P
Department of Clinical Chemistry, University of Helsinki, Helsinki, Finland. patrik.finne@hus.fi
Stenman
U H
UH
Määttänen
L
L
Mäkinen
T
T
Tammela
T L J
TL
Martikainen
P
P
Ruutu
M
M
Ala-Opas
M
M
Aro
J
J
Karhunen
P J
PJ
Lahtela
J
J
Rissanen
P
P
Juusela
H
H
Hakama
M
M
Auvinen
A
A
D000368:Aged; D001706:Biopsy / Q000379:methods; D003362:Cost-Benefit Analysis; D005387:Finland / Q000453:epidemiology; D006801:Humans; D008297:Male; D008403:Mass Screening / Q000379:methods*; D008875:Middle Aged; D010375:Pedigree; D011379:Prognosis; D011467:Prostate / Q000473:pathology*; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000401:mortality; D011788:Quality of Life
D017430:Prostate-Specific Antigen